Home > Insider Trading > Filing (0000899243-21-039704)

Filing Details

Accession Number:: 0000899243-21-039704
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-10-08 16:33:08
Reporting Period:: 2021-10-06

Accepted Time:: 2021-10-08 16:33:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689548	Praxis Precision Medicines Inc.	PRAX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1070844	A Stephen Schwarzman	C/O Blackstone Inc. 345 Park Avenue New York NY 10154	No	No	Yes	No
1393818	Blackstone Inc	345 Park Avenue New York NY 10154	No	No	Yes	No
1404071	L.l.c. Management Group Blackstone	C/O Blackstone Inc. 345 Park Avenue New York NY 10154	No	No	Yes	No
1464694	L.p. I Holdings Blackstone	C/O Blackstone Inc. 345 Park Avenue New York NY 10154	No	No	Yes	No
1464695	L.l.c. Gp I/Ii Holdings Blackstone	C/O Blackstone Inc. 345 Park Avenue New York NY 10154	No	No	Yes	No
1484870	L.p. Ii Holdings Blackstone	C/O Blackstone Inc. 345 Park Avenue New York NY 10154	No	No	Yes	No
1728529	L.l.c. Associates Opportunity Strategic Blackstone	C/O Blackstone Inc. 345 Park Avenue New York NY 10154	No	No	Yes	No
1728531	L.l.c. Solutions Alternative Blackstone	C/O Blackstone Inc. 345 Park Avenue New York NY 10154	No	No	Yes	No
1736665	L.p. Fund Master Parallel Bsof	C/O Blackstone Inc. 345 Park Avenue New York NY 10154	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-10-06	400,000	$17.50	0	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,894,109	Indirect	See Footnotes

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.50 to $18.48, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price in the range set forth in this footnote.
Reflects securities held directly by BSOF Parallel Master Fund L.P. Blackstone Strategic Opportunity Associates L.L.C. is the general partner of BSOF Parallel Master Fund L.P. Blackstone Holdings II L.P. is the sole member of Blackstone Strategic Opportunity Associates L.L.C. Blackstone Alternative Solutions L.L.C. is the investment manager of BSOF Parallel Master Fund L.P. Blackstone Holdings I L.P. is the sole member of Blackstone Alternative Solutions L.L.C.
Reflects securities held directly by Clarus Lifesciences III, L.P. Clarus Ventures III GP, L.P. is the general partner of Clarus Lifesciences III, L.P. Blackstone Clarus III L.L.C. is the general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P.
The general partner of each of Blackstone Holdings I L.P. and Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is Blackstone Inc. The sole holder of the Series II preferred stock of Blackstone Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.